


Infectious Disease

LIAISON[®] Mumps IgG and IgM

The fully automated solution
for antibody detection



DiaSorin

The Diagnostic Specialist

FOR OUTSIDE THE US AND CANADA ONLY

Mumps: transmission and infection


- Mumps is a viral illness caused by a member of the *Paramyxoviridae* family.
- The mumps virus is transmitted by respiratory droplets. It has an incubation period of 14-25 days after which time prodromal symptoms occur and last anywhere from 3-5 days.
- Most commonly manifested as a salivary gland infection but sometimes can cause meningitis, deafness and pancreatic, testicular or ovarian inflammation.

Vaccination

- MMR Vaccine have had a marked effect on the incidence of the disease and the complications associated with it.
- After prolonged periods of high vaccine coverage in developed countries, mumps transmission now occurs mainly in people that have never been vaccinated and in older children who did not seroconvert following vaccination.
- Immunization against mumps has been associated with a marked decline in the incidence of mumps disease in many European countries, but there are also indications that vaccine effectiveness may be lower than what the vaccine efficacy studies indicate.

Clinical diagnostic and serology

- IgM is detectable initially within 3 to 4 days of the appearance of clinical symptoms and persists for 8 to 12 weeks.
- IgG is detectable within 7 to 10 days of the onset of symptoms, is maintained at high levels for years, and remains detectable for life.
- A significant increase in IgG titres, equal to or greater than four fold, from paired specimens collected 3-4 weeks apart indicates current or recent infection.



INTERPRETATION OF SEROLOGY RESULTS

Result	Indication
IgG+, IgM-	Past infection (immune)
IgG-, IgM-	No Past infection (non-immune) At risk of infection
IgG+, IgM+	Implies recent or Current infection
IgG-, IgM+	Implies recent or Current infection

Bibliography


1. Murray P.R., et al, Manual of Clinical Microbiology-ASM press 9th edition 2007, pp 1378-1383
2. World Health Organization - Department of Immunization, Vaccines and Biologicals
www.who.int/vaccines-documents/
3. Immunisation against infectious disease - 'The Green Book' - chapter 21 2006 Edition
4. European Center for Disease Prevention and Control www.ecdc.europa.eu

LIAISON® Mumps IgG and IgM Assays

The fully automated approach to Mumps IgG and IgM antibody detection

The unique technological advantages of the LIAISON® system, the quality of the reagents and antigen selection have been combined to create a new approach to the Mumps diagnosis.


LIAISON® Mumps IgG



Diagnostic Sensitivity	98,5%
	(95% C.I.: 96.5-99.5%)
Diagnostic Specificity	98,2%
	(95% C.I.: 94.8-99.2%)

Diagnostic performance was assessed by testing 519 unselected specimens collected from an European laboratory routine against a commercially available reference EIA.

LIAISON® Mumps IgM



Diagnostic Sensitivity	95.2%
	(95% C.I.: 88.3-98.7%)
Diagnostic Specificity	99,5%
	(95% C.I.: 98.3-99.9%)

Diagnostic performance was assessed by testing 550 unselected specimens collected from an European laboratory routine against a commercially available reference EIA.

Recombinant Antigen expressed in *Pichia pastoris*

- Correct folding and conformation of protein.
- Antigen most resembling the native virus.
- Consistent detection of antibody throughout all phases of the immune response.
- Optimal configuration of assays for sensitivity and specificity.

Infectious Disease

LIAISON® Mumps Assays

LIAISON® Mumps IgG

Number of tests	100
Assay format	Indirect-Quantitative
Method	CLIA
Antigen type	Recombinant nucleoprotein expressed in <i>Pichia pastoris</i>
Label	Isoluminol Derivative
Sample type	20 uL Serum / Plasma
Integral on board stability	8 weeks
Calibrators availability	on board
Calibration stability	4 weeks
Controls availability	Positive and Negative
Controls stability once opened	8 weeks

LIAISON® Mumps IgM

Number of tests	50
Assay format	Indirect-Qualitative
Method	CLIA
Antigen type	Recombinant nucleoprotein expressed in <i>Pichia pastoris</i>
Label	Isoluminol Derivative
Sample type	20 uL Serum / Plasma
Integral on board stability	8 weeks
Calibrators availability	on board
Calibration stability	4 weeks
Controls availability	Positive and Negative
Controls stability once opened	8 weeks

Ordering Information	Code
LIAISON® Mumps IgG	318840
LIAISON® Control Mumps IgG	318841
LIAISON® Mumps IgM	318830
LIAISON® Control Mumps IgM	318831

AVAILABLE ON **LIAISON®** SYSTEMS

Product availability subject to required regulatory approval

DiaSorin

The Diagnostic Specialist

DiaSorin S.p.A.
Via Crescentino, snc
13040 Saluggia (VC) Italy
Tel. +39 0161 487 526/947
Fax +39 0161 487 670
www.diasorin.com
info@diasorin.it

M0870003986/A 12329 04/13